 Conformis Inc NASDAQ: CFMS announced results of a published retrospective study of procedures using Conformis patient-specific iTotal CR cruciate-retaining knee replacement implant. Data showed that implant survivorship was 98.5 with 8 revisions representing 1.5 of the 540 implants reviewed at a mean follow-up of 2.8 years. 